U.S. Markets closed

VAPE Holdings Files for Additional Cannabis-Derived Patent Rights

NG 200 Series Patent Application Focuses on High-Value Biomedical Applications

CHATSWORTH, CA / ACCESSWIRE / May 19, 2015 / VAPE Holdings, Inc. (VAPE) (the "Company" or "VAPE"), a holding company focused on providing healthy, efficient, and sustainable products to lawfully operating participants in the legal cannabis industry, is pleased to announce that it has filed a second application with the US Patent and Trademark Office ("USPTO") for a new class of cannabis-derived products for high-value bio-medical applications. VAPE has designated its new biomedical patent application, and all of its subparts, as the "NG 200 Series Patents."

"Our filing with the USPTO expands VAPE's intellectual property portfolio to include new, high-value cannabis-derived materials and products for the biomedical field," according to VAPE Holdings Chief Executive Officer Kyle Tracey. "The VAPE NG 200 Series Patent applications that we have announced today represent another exciting step forward in our expansion into proprietary, next generation technology," Tracey remarked.

"This patent application is for processes and methods of delivering specific cannabinoid formulations in treatment of a wide range of diseases and medical conditions," explained VAPE Holdings Chief Science Officer Dr. Mark Scialdone. "Our expectation is that our innovations will be of particular interest to the medical community in the treatment of conditions in which successful therapeutic outcome is dependent on localized control of inflammation and pain," added Dr. Scialdone.

With the worldwide market for bio-medical materials in excess of 3 billion dollars, and with attractive growth rates between 10-15%, there exists a considerable opportunity to meet the increasing demand that modern healthcare demands for medical devices and drug delivery formulations.

With its initial patent filing complete, the VAPE team will focus on relatively low cost pre-clinical testing to demonstrate efficacy and safety of preferred delivery methods. VAPE seeks to monetize its NG 200 Series Patents through licensing and partnering relationships with one or more of the increasing number of pharmaceutical companies and medical device companies that are engaged in product development in the legal cannabis space.

About Vape Holdings, Inc.

VAPE Holdings, Inc. focuses on designing, marketing, and distributing various vaporization products and provides management, consulting, branding, real estate and compliant packaging solutions to lawfully operating participants in the legal cannabis industry. The company offers medical and food grade ceramic products primarily under the HIVE Ceramics brand throughout North America, Europe and South America. HIVE offers a nonporous, non-corrosive, chemically inert ceramic vaporization element, which can be used for a range of applications, including stand-alone vaporization products and electronic cigarettes. The company is based in Chatsworth, California.

For more information on HIVE Ceramics and to visit our e-commerce site, please visit: http://www.hiveceramics.com

From time to time, VAPE Holdings will provide market updates and news via its website http://www.vapeholdings.com/ or the Company's Facebook page at http://on.fb.me/1d5c7iO

Cautionary Language Concerning Forward-Looking Statements

This release contains "forward-looking statements" that include information relating to future events and future financial and operating performance. The words "may," "would," "will," "expect," "estimate," "can," "believe," "potential" and similar expressions and variations thereof are intended to identify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause these differences include, but are not limited to: fluctuations in demand for VAPE Holdings' products, the introduction of new products, the Company's ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company's liquidity and financial strength to support its growth, and other information that may be detailed from time-to-time in VAPE Holdings' filings with the United States Securities and Exchange Commission. Examples of such forward-looking statements in this release include statements regarding future sales, costs and market acceptance of products as well as regulatory actions at the State or Federal level. For a more detailed description of the risk factors and uncertainties affecting VAPE Holdings please refer to the Company's Securities and Exchange Commission filings, which are available at www.sec.gov. VAPE Holdings undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

Investor Relations:
Hayden IR

SOURCE: Vape Holdings, Inc.